Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200029/S012

TheraSphere

BOSTON SCIENTIFIC CORPORATION · Decision date Apr 10, 2026

FDA DECISIONP200029/S012

What did the FDA approve?

FDA records P200029/S012 as a supplement to PMA P200029, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Apr 10, 2026.

FDA approval order statement

Approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P200029/S011.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Radiology
Decision date
Apr 10, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P200029/S012
Regulatory pathway
PMA supplement
Product code
NAW
Decision code
APPR
Decision date
Apr 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Microspheres radionuclide.

Product code
NAW
FDA device class
3

For the original device and its historical approval scope, see PMA P200029. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200029/S012 received

    Application receipt date recorded by FDA.

  2. P200029/S012 · FDA decision

    Normal 180 Day Track No User Fee

  3. P200029/S013 · Related supplement

    TheraSphere Y-90 Glass Microspheres System

  4. P200029/S015 · Related supplement

    TheraSphere Y-90 Glass Microspheres System

Timeline entries are records held by MedtechLedger for P200029. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200029

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA approvalMar 17, 2021FDA
TheraSphereP200029/S011
BOSTON SCIENTIFIC CORPORATIONPMA supplementFeb 10, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementJun 4, 2026FDA
TheraSphereP200029/S014
BOSTON SCIENTIFIC CORPORATIONPMA supplementAug 21, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementOct 13, 2026FDA

Explore the linked device profile

Other records with product code NAW

Product / regulatory recordCompanyPathwayDecision dateSource
Sirtex Medical, Inc.PMA supplementMay 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
300 Boston Scientific Way, Marborough, MA, 01752

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records